Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SNF2-related chromatin remodeling ATPase 1 (SMARCA1)
- Target
- SMARCA1
- Molecular classification
- Chromatin remodeling enzyme, ATP-dependent helicase, Enzyme
01
Overview
SNF2-related chromatin remodeling ATPase 1 (SMARCA1) is an ATP-dependent enzyme that is a core catalytic component of ISWI-family chromatin remodeling complexes, including roles in nucleosome positioning and DNA accessibility within chromatin. SMARCA1 (also called SNF2L) participates in transcriptional activation and repression, impacting cellular differentiation (notably in neural progenitors), DNA repair pathways, and cell cycle control. Altered SMARCA1 function or expression, via genetic or epigenetic mechanisms, has been linked to cancer and neurodevelopmental disorders. It operates by hydrolyzing ATP to remodel nucleosomes, thereby influencing the transcriptional landscape of cells[3][5][1]. So far, no drugs directly target SMARCA1, but its activity and expression pattern are under investigation as biomarkers in oncology, and its biology highlights both therapeutic opportunities and significant safety challenges for global chromatin regulators.
- Other names
- SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1SNF2LSNF2L1SNF2LBNURF140ISWISWIhSNF2LNucleosome-remodeling factor subunit SNF2LATP-dependent helicase SMARCA1SNF2-like 1Global transcription activator SNF2L1Sucrose nonfermenting 2-like protein 1
02
Mechanism of action
Not established for drugs; generally, the mechanism involves ATP-dependent chromatin remodeling affecting gene expression and DNA accessibility
03
Biological functions
Chromatin remodelingRegulation of gene expression and transcriptionCell differentiation (especially neural differentiation)Nucleosome spacing and DNA accessibility
04
Disease associations
CancerNeurodevelopmental disorders
05
Safety considerations
No established therapeutic drugs targeting SMARCA1, so specific safety concerns for direct targeting unknownGeneral challenges: chromatin remodelers have broad effects—potential for unintended alterations in global gene regulation if targeted
06
Biomarkers
SMARCA1 expression level (as a potential biomarker for prognosis and diagnosis in certain cancers)Phosphorylation of S116 (noted in cancer pathway studies)
Beyond the preview
Go deeper on SNF2-related chromatin remodeling ATPase 1 (SMARCA1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNF2-related chromatin remodeling ATPase 1 (SMARCA1).